Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 4677-4683

  Muche, Sylvia ^a   Kirschnick, Melissa ^a   Schwarz, Michael ^a   Braeuning, Albert ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Hepatocellular carcinoma; Liver tumor; MAPK signaling; Wnt signaling

Indexed keywords

2 [((2 (4 ETHYLPHENYL) 5 METHYL 4 OXAZOLYL)METHYL)THIO] N (2 PHENYLETHYL)ACETAMIDE; ANTINEOPLASTIC AGENT; BETA CATENIN; BROXURIDINE; DIMETHYL SULFOXIDE; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE; N (2 METHYL 4 NITRO) 2,4 DICHLOROSULFONAMIDE; PROTEIN INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG; WNT1 PROTEIN; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HEPATOMA CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; RNA ISOLATION; STAINING; TRANSACTIVATION; ANIMAL; CELL MOTION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; LIVER TUMOR; MAPK SIGNALING; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WNT SIGNALING;

HEPATOCELLULAR CARCINOMA; LIVER TUMOR; MAPK SIGNALING; WNT SIGNALING;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; LIVER NEOPLASMS; MICE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84908668613     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lin S, Hoffmann K and Schemmer P: Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 1: 144-158, 2012.
2. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006.
3. Cao H, Phan H and Yang LX: Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 32: 1379-1386, 2012.
4. Schmidt CM, McKillop IH, Cahill PA and Sitzmann JV: Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236: 54-58, 1997.
5. Takigawa Y and Brown AM: Wnt signaling in liver cancer. Curr Drug Targets 9: 1013-1024, 2008.
6. Thompson MD and Monga SP: WNT/β-catenin signaling in liver health and disease. Hepatology 45: 1298-1305, 2007.
7. Behrens J and Lustig B: The Wnt connection to tumorigenesis. Int J Dev Biol 48: 477-487, 2004.
8. Cavard C, Colnot S, Audard V, Benhamouche S, Finzi L, Torre C, Grimber G, Godard C, Terris B and Perret C: Wnt/β-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol 4: 647-660, 2008.
9. Calvisi DF, Ladu S, Factor VM and Thorgeirsson SS: Activation of β-catenin provides proliferative and invasive advantages in cmyc/TGF-α hepatocarcinogenesis promoted by phenobarbital. Carcinogenesis 25: 901-908, 2004.
10. Orford K, Orford CC and Byers SW: Exogenous expression of β-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J Cell Biol 146: 855-868, 1999.
11. Kim K, Pang KM, Evans M and Hay ED: Overexpression of β-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol Biol Cell 11: 3509-3523, 2000.
12. Zeller E, Hammer K, Kirschnick M and Braeuning A: Mechanisms of RAS/beta-catenin interactions. Arch Toxicol 87: 611-632, 2013.
13. Wei Y, Shen N, Wang Z, Yang G, Yi B, Yang N, Qiu Y and Lu J: Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling. Mol Cell Biochem 381: 139-144, 2013.
14. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL and Llovet JM: Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 18: 4997-5007, 2012.
15. Huynh TT, Rao YK, Lee WH, Chen HA, Le TD, Tzeng DT, Wang LS, Wu AT, Lin YF, Tzeng YM and Yeh CT: Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition. Toxicol In Vitro 28: 552-561, 2014.
16. Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT and Gedaly R: Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. Anticancer Res 34: 1709-1713, 2014.
17. Mologni L, Brussolo S, Ceccon M and Gambacorti-Passerini C: Synergistic effects of combined WNT/KRAS inhibition in colorectal cancer cells. PLoS One 7: e51449, 2012.
18. Braeuning A, Menzel M, Kleinschnitz EM, Harada N, Tamai Y, Kohle C, Buchmann A and Schwarz M: Serum components and activated Ha-ras antagonize expression of perivenous marker genes stimulated by β-catenin signaling in mouse hepatocytes. Febs J 274: 4766-4777, 2007.
19. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A and Schwarz M: Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of β-catenin-mutated mouse liver tumors. Oncogene 20: 7812-7816, 2001.
20. Jaworski M, Buchmann A, Bauer P, Riess O and Schwarz M: Braf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene 24: 1290-1295, 2005.
21. Braeuning A, Vetter S, Orsetti S and Schwarz M: Paradoxical cytotoxicity of tert-butylhydroquinone in vitro: What kills the untreated cells? Arch Toxicol 86: 1481-1487, 2012.
22. Ring L, Perobner I, Karow M, Jochum M, Neth P and Faussner A: Reporter gene HEK 293 cells and WNT/Frizzled fusion proteins as tools to study WNT signaling pathways. Biol Chem 392: 1011-1020, 2011.
23. Braeuning A and Vetter S: The nuclear factor KB inhibitor (E)-2-fluoro-4′-methoxystilbene inhibits firefly luciferase. Biosci Rep 32: 531-537, 2012.
24. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
26. Wanke I, Schwarz M and Buchmann A: Insulin and dexamethasone inhibit TGF-beta-induced apoptosis of hepatoma cells upstream of the caspase activation cascade. Toxicology 204: 141-154, 2004.
27. Sinnberg T, Menzel M, Ewerth D, Sauer B, Schwarz M, Schaller M, Garbe C and Schittek B: β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One 6: e23429, 2011.
28. Liang CC, Park AY and Guan JL: In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333, 2007.
29. Braeuning A, Kohle C, Buchmann A and Schwarz M: Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the betacatenin pathway. Toxicol Sci 122: 16-25, 2011.